Antitumor Antibiotics

  • S. K. Carter
  • Hamao Umezawa
  • John Douros
  • Yoshio Sakurai

Table of contents

  1. Front Matter
    Pages I-IX
  2. H. L. Davis Jr., D. D. Von Hoff, J. E. Henney, M. Rozencweig
    Pages 21-29
  3. L. J. Hanka, S. L. Kuentzel, D. G. Martin, P. F. Wiley, Gary L. Neil
    Pages 69-76
  4. R. H. Bunge, D. E. McCready, L. A. Balta, B. D. Graham, J. C. French, H. W. Dion
    Pages 77-84
  5. P. S. Schein, J. S. MacDonald, D. Hoth, P. V. Woolley
    Pages 148-151
  6. M. Abe, Y. Shigematsu, S. Kimura
    Pages 169-178
  7. A. Matsuda, O. Yoshioka, T. Yamashita, K. Ebihara, H. Umezawa, T. Miura et al.
    Pages 191-210
  8. N. Yamanaka, M. Fukushima, T. Kato, K. Koizumi, K. Ota
    Pages 211-218
  9. S. T. Crooke, R. I. Comis, L. H. Einhorn, J. E. Strong, A. Broughton, A. W. Prestayko
    Pages 219-229
  10. H. Furue, T. Komita, I. Nakao, I. Furukawa, T. Kanko, T. Yokoyama
    Pages 241-246
  11. H. Furue, T. Komita
    Pages 247-251
  12. R. L. Comis, T. Griffin, V. Raso, S. J. Ginsberg
    Pages 261-271
  13. Back Matter
    Pages 305-306

About this book


The scientific collaboration between the United States and Japan in the field of cancer goes back many years. In this successful international collaboration cancer chemotherapy has been one of the most productive areas. Pioneers such as YOSHIDA, UMEZAWA, SHEAR, and GOLDIN established firm links of mutual trust and respect in the period after the Second Great War. Japanese drugs, such as mitomycin C and bleomycin have become mainstays of clinical oncology in the U. S. and throughout the world. Many drugs developed in the U. S. have become established in Japanese cancer therapy. Within the cancer chemotherapy field the antitumor antibiotics rank as one of the most important groups. In the U . S. -J apanese collaboration this group of drugs has taken the paramount role. The Japanese, under the leadership of U mezawa, are considered to be among the most innovative and productive in this area which has also had great emphasis in the United States as part of the National Cancer Institute's drug development program and in the pharmaceutical industry. This extended collaboration in general oncology, and chemotherapy in particular, has received increased impetus by and support from the official U . S. -J apan Joint Agreement on cancer research, which was established in 1974 between the National Cancer Institute and the Japanese Society for the Promotion of Science. One of the subsections of this agreement is cancer therapy with emphasis on chemotherapy.


antibiotics cancer cancer research cancer therapy chemotherapy oncology therapy

Editors and affiliations

  • S. K. Carter
    • 1
  • Hamao Umezawa
    • 2
  • John Douros
    • 3
  • Yoshio Sakurai
    • 4
  1. 1.Northern California Cancer ProgramPalo AltoUSA
  2. 2.Department of AntibioticsNational Institutes of HealthShinagawa-ku, TokyoJapan
  3. 3.Division of Cancer TreatmentNational Cancer InstituteSilver SpringUSA
  4. 4.Cancer Chemotherapy CenterJapanese Foundation for Cancer ResearchToshima-ku, TokyoJapan

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1978
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-81221-7
  • Online ISBN 978-3-642-81219-4
  • Series Print ISSN 0080-0015
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Consumer Packaged Goods